CBIZ Investment Advisory Services LLC Buys 364 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

CBIZ Investment Advisory Services LLC grew its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 163.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 587 shares of the biotechnology company’s stock after purchasing an additional 364 shares during the quarter. CBIZ Investment Advisory Services LLC’s holdings in Sarepta Therapeutics were worth $71,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Janus Henderson Group PLC boosted its stake in shares of Sarepta Therapeutics by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after acquiring an additional 543,143 shares during the period. Wellington Management Group LLP lifted its holdings in Sarepta Therapeutics by 32.3% during the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after purchasing an additional 665,087 shares during the last quarter. Geode Capital Management LLC boosted its stake in Sarepta Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after purchasing an additional 44,306 shares during the period. Jacobs Levy Equity Management Inc. grew its stake in shares of Sarepta Therapeutics by 9.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company’s stock valued at $94,148,000 after acquiring an additional 63,437 shares in the last quarter. Finally, Erste Asset Management GmbH boosted its holdings in Sarepta Therapeutics by 11.3% in the 4th quarter. Erste Asset Management GmbH now owns 708,248 shares of the biotechnology company’s stock valued at $86,116,000 after purchasing an additional 72,183 shares during the period. Institutional investors own 86.68% of the company’s stock.

Insider Activity at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 7.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Piper Sandler lowered their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. HC Wainwright restated a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. Needham & Company LLC restated a “buy” rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 27th. Finally, Scotiabank started coverage on Sarepta Therapeutics in a research note on Friday, March 7th. They issued a “sector perform” rating and a $105.00 price objective for the company. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $170.41.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $97.19 on Friday. Sarepta Therapeutics, Inc. has a 52 week low of $97.06 and a 52 week high of $173.25. The company’s 50 day moving average price is $111.73 and its two-hundred day moving average price is $119.96. The stock has a market cap of $9.43 billion, a P/E ratio of 77.75 and a beta of 0.79. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.